收藏切换
The clinical efficacy of tislelizumab combined with Nab-PP in the treatment of advanced lung squamous cell carcinoma with high PD-L1 expression
收藏切换
Meng LI, Xueqin ZHANG, Chenyang ZHAO, Yuan XING*
World Clinical Drug | 2025, 46(12) : 1290 - 1297
Less
收藏切换
World Clinical Drug | 2025, 46(12): 1290-1297
• Article •
The clinical efficacy of tislelizumab combined with Nab-PP in the treatment of advanced lung squamous cell carcinoma with high PD-L1 expression
Full
Meng LI, Xueqin ZHANG, Chenyang ZHAO, Yuan XING*
Affiliations
  • Department of Pharmacy, Intravenous Drug Dispensing Center, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei Province, China
Published: 2025-12-10 doi: 10.13683/j.wph.2025.12.014
Outline
收藏切换
Objective

To explore the clinical study of tislelizumab combined with nab-paclitaxel and cisplatin(Nab-PP) for advanced lung squamous cell carcinoma with high expression of programmed death-ligand(PD-L)1.

Methods

The clinical data of patients with advanced lung squamous cell carcinoma with high PD-L1 expression who were admitted to our hospital from November 2020 to June 2023 were retrospectively collected. A total of 99 patients who received Nab-PP combined with tislelizumab treatment(the monoclonal antibody group), and 91 patients who received only Nab-PP treatment during the same period(the reference group) were initially included. The propensity score matching method was adopted, and the matching was carried out according to the 1∶1 ratio principle. Eventually, 52 patients in each group were successfully matched. The clinical efficacy, immune indicators, tumor markers, degree of primary lesion remission, functional status, quality of life scores, survival situation and safety between the two groups were compared.

Results

The objective response rate of the monoclonal antibody group(55.77%) was higher than that of the reference group(32.69%, P<0.05). After treatment, the levels of CD3+, CD4+, CD4+/CD8+ and natural killer cells in the monoclonal antibody group were all higher than those in the reference group, while the levels of squamous cell carcinoma antigen, carcinoembryonic antigen, cytokeratin 19 fragment and matrix metalloproteinase 9 were all lower than those in the reference group(P<0.05). In the monoclonal antibody group, there were 18 cases in stage Ⅲb. Among them, 16 cases(88.9%) eventually underwent radical surgery. Postoperative pathology confirmed 9 cases(56.3%) of major pathological response and 7 cases(43.8%) of pathological complete response. After the treatment, the Karnofsky performance status and the systematic evaluation of pulmonary function - lung score of the monoclonal antibody group were both higher than those of the reference group(P<0.05). The median progression-free survival and overall survival in the monoclonal antibody group were significantly higher than those in the reference group(χ2=13.882, 12.323, P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).

Conclusion

Tislelizumab combined with the Nab-PP regimen can significantly improve the clinical efficacy of patients with advanced lung squamous cell carcinoma with high PD-L1 expression, prolong survival time, and has a good safety profile. It is suitable for clinical promotion and application.

tislelizumab  /  paclitaxel  /  cisplatin  /  lung squamous cell carcinoma  /  clinical efficacy  /  safety
李萌, 张学琴, 赵晨阳, 邢源. 替雷利珠单抗联合Nab-PP治疗PD-L1高表达晚期肺鳞癌的临床疗效. 世界临床药物, 2025 , 46 (12) : 1290 -1297 . DOI: 10.13683/j.wph.2025.12.014
Meng LI, Xueqin ZHANG, Chenyang ZHAO, Yuan XING. The clinical efficacy of tislelizumab combined with Nab-PP in the treatment of advanced lung squamous cell carcinoma with high PD-L1 expression[J]. World Clinical Drug, 2025 , 46 (12) : 1290 -1297 . DOI: 10.13683/j.wph.2025.12.014
Year 2025 volume 46 Issue 12
59
10
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2025.12.014
  • Receive Date:2025-04-08
  • Online Date:2026-11-09
  • Published:2025-12-10
Article Data
Affiliations
History
  • Received:2025-04-08
Funding
Affiliations
    Department of Pharmacy, Intravenous Drug Dispensing Center, the First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.12.014
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT